MetaCap

Design Therapeutics Inc. (DSGN)

NASDAQ: DSGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

9.02-0.30 (-3.22%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

DSGN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$577.61M
EPS (TTM)
-$1.20
52-week range
8.21 – 17.25
Day range
8.97 – 9.57
Volume / Avg
281.93K / 554.69K
Beta
—

52-week range

$8.21$17.25

DSGN stock today

Design Therapeutics (DSGN) closed at $9.02 on Nov 20, down 3.22% (-$0.30), versus the S&P 500's 3.70% decline. At this level, DSGN sits near the bottom of its 52-week range of $8.21 to $17.25: 47.7% below the high, set on Apr 29, 2026 and 9.9% above the low. DSGN is down 3.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 8.0%.

Design Therapeutics has posted a net loss over the last twelve months (EPS of -$1.20), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Design Therapeutics

Company profile

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Pratik Shah Ph.D.
Headquarters
Carlsbad, CA
Employees
60
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Design Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Design Therapeutics reported a net loss of $69.8 million, compared with a loss of $49.6 million a year earlier. Diluted earnings per share came in at -$1.22.

Design Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$0———
Growth—————
Net income$-69.79M$-49.59M$-66.86M$-63.31M$-35.53M
EPS (diluted)$-1.22$-0.88$-1.19$-1.14$-0.77

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$21.57+139.14%

  • Strong buy 2
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $19.00High $26.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.32 vs $-0.38
Surprise
+15.79%

DSGN news

All DSGN news

Design Therapeutics peers

Health Care sector
DSGN peer companies
CompanyPrice% ChgMarket capCompare
IMMXImmix Biopharma Inc.6.96-1.14%$583.33Mvs DSGN
ANNXAnnexon Inc.3.10-9.09%$591.37Mvs DSGN
GERNGeron Corporation0.8707-4.63%$560.94Mvs DSGN
BCAXBicara Therapeutics Inc.8.44-7.46%$560.31Mvs DSGN
ANLAdlai Nortye Group Ltd. ADR8.55-5.63%$550.60Mvs DSGN
ACRSAclaris Therapeutics Inc.3.44-1.71%$545.63Mvs DSGN
AVBPArriVent BioPharma Inc.10.52-6.57%$544.13Mvs DSGN
CBIOCrescent Biopharma Inc.13.00+0.70%$543.21Mvs DSGN

Indexes, lists and sector

Design Therapeutics stock FAQ

What is Design Therapeutics's stock price today?

DSGN last traded at $9.02 as of Nov 20, 4:00 PM EST, down 3.22% on the day. Prices are delayed at least 15 minutes.

Who is Design Therapeutics's CEO?

Mr. Pratik Shah Ph.D. is the chief executive officer of Design Therapeutics Inc., which has about 60 employees.

What is the DSGN 52-week high?

The 52-week high for DSGN is $17.25 and the 52-week low is $8.21. The stock is currently 47.7% below its high.

Compare DSGN